Abstract:G protein-coupled receptor 120 (GPR120) is a Gαq coupled GPCR specifically activated by long-chain fatty acids (LCFAs). Functionally, it has been identified as a member of a family of lipid-binding free fatty acid receptors including GPR40, GPR41, and GPR43. Upon stimulation by LCFAs, GPR120 can directly or indirectly modulate hormone secretion from the gastrointestinal tract and pancreas, and regulate lipid and/or glucose metabolism in adipose, liver, and muscle tissues. Additionally, GPR120 is postulated to mediate anti-inflammatory and insulin-sensitizing effects in adipose and macrophages. These benefits suggest that GPR120 agonists have the potential to be an effective treatment for obesity, type 2 diabetes mellitus (T2DM), and other metabolic syndromes.This article highlights and reviews research advances in this field that have been published in patent literature and peer-reviewed journals since 2014.Current development has been hindered by species differences in GPR120 distribution, differences in GPR120-mediated signaling in distinct tissue types, and lack of available ligands with suitable selectivity for GPR120 over GPR40 in both human and rodents. The discovery of β-arrestin biased GPR120 agonists will help elucidate the potential of selective therapeutics that may discriminate between desirable and undesirable pharmacological effects.ALA: α-linolenic acid; AUC: area under the curve; BRET: bioluminescence resonance energy transfer; CCK: cholecystokinin; CHO-K1 cell: Chinese hamster ovary-K1 cell; db/db mouse: diabetic mouse; DHA: docosahexaenoic acid; DIO: diet-induced obesity; DMSO: dimethyl sulfoxide; DPP-4: dipeptidyl peptidase 4; EPA: eicosapentaenoic acid; FA(s): fatty acid(s); FFA(s): free fatty acid(s); FFAR: free fatty acid receptor; FLIPR: fluorescent imaging plate reader; GIR: glucose infusion rate; GLP-1: glucagon-like peptide 1; GP(C)R: G protein-coupled receptor; GSIS: glucose-stimulated insulin secretion; HEK293 cell: human embryonic kidney 293 cell; HOMA-IR: homeostatic measurement assessment of insulin resistance; IP1: inositol phosphate turnover; IPGTT: intraperitoneal glucose tolerance test; LCFA(s): long-chain fatty acid(s); MEDmax: maximal efficacy; MIN6 cell: mouse insulin-secreting cell; NPY: neuropeptide Y; OGTT: oral glucose tolerance test; pERK: phosphorylated ERK; PPAR: peroxisome proliferator-activated receptor; QD: once daily; SAR: structure–activity relationship; siRNA: small interfering ribonucleic acid; STC-1: intestinal secretin tumor cell; T2DM: type 2 diabetes mellitus; U2OS cell: human bone osteosarcoma epithelial cell; uHTS: ultrahigh-throughput screening; ZDF: zucker diabetic fatty.

What is holding back preclinical GPR119 agonists from their potential as the therapeutics of type 2 diabetes?

GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates

Structure of human GPR119-Gs complex binding APD597 and characterization of GPR119 binding agonists

GPR120 agonists for the treatment of diabetes: a patent review (2014 present)

GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119

Deciphering G-Protein-Coupled Receptor 119 Agonists As Promising Strategy Against Type 2 Diabetes Using Systems Biology Approach

First GPR119 PET Imaging Ligand: Synthesis, Radiochemistry, and Preliminary Evaluations

Targeting lipid GPCRs to treat type 2 diabetes mellitus — progress and challenges

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: the Biological Characteristics and the Chemical Space

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells

Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1h)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119.

Targeting GLP-1 receptor trafficking to improve agonist efficacy

G protein-coupled receptors as new therapeutic targets for type 2 diabetes

Lipid receptors and islet function: therapeutic implications?

G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

Discovery of Novel and Selective GPR17 Antagonists as Pharmacological Tools for Developing New Therapeutic Strategies in Diabetes and Obesity

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells

The clinical experience of GLP-1 receptor agonist drugs

The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent